Deutsche Bank weighs in on Anacor's (ANAC -22.5%) weakness on its tavaborole Phase 3 data...

|About: Anacor Pharmaceuticals, Inc. (ANAC)|By:, SA News Editor

Deutsche Bank weighs in on Anacor's (ANAC -22.5%) weakness on its tavaborole Phase 3 data release, saying that ANAC's patient population may have been older and less healthy versus Valeant's (VRX +0.8%) Phase 3 trials, and its mycological cure rate was actually superior to VRX's results.